For patients with solid tumours, vascular abnormalities can enable the tumour to evade surveillance and attack by the immune system, and these abnormalities arise from elevated angiogenic factors such as VGEF and angiopoietin 2 (ANG2). This evidence concerns the gene ANGPT2 and neoplasm.